RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
March 15, 2022
RegMed Investors’ (RMi) closing bell: it’s about time for the oversold cell and gene therapy sector logjam to come back to appreciation
March 14, 2022
RegMed Investors’ (RMi) closing bell: just when I thought sentiment would rebound and lift the cell and gene therapy sector
March 11, 2022
RegMed Investors’ (RMi) closing bell: escalated depreciation in the cell and gene therapy sector
March 10, 2022
RegMed Investors’ (RMi) closing bell: the algorithms beat me to the profit window
March 10, 2022
RegMed Investors’ (RMi) pre-open: time to take some chips off the table
March 9, 2022
RegMed Investors’ (RMi) closing bell: a pocket of appreciation, how long will it last?
March 9, 2022
RegMed Investors’ (RMi) pre-open: tread lightly, add, trim or hedge as needed
March 8, 2022
RegMed Investors’ (RMi) closing bell: news, earnings and oversold conditions drive sector’s risk slide
March 4, 2022
RegMed Investors’ (RMi) closing bell: the advance/decline line pooped the stoop
March 3, 2022
RegMed Investors’ (RMi) closing bell: a worried sector, downtrodden by war anxieties
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.